Profit-Taking Hits Moderna Stock After mRNA-1010 Wins Unanimous FDA Panel Backing
Decision due Aug 5, 2026. Potential 2026–27 launch.
/ 22 items
#MRNA↓
Moderna Strengthens Commercial Leadership Ahead of Flu and Norovirus Vaccine Launches
Moderna names Ester Banque, ex-Zoetis/Novartis, as Chief Commercial Officer as it prepares for potential 2027 launches of combined flu-COVID, standalone flu, and norovirus vaccines. FDA advisory on mFLUSIVA this week.
Moderna Stock Surges as Hantavirus Vaccine Research Lights Up After Cruise Ship Outbreak
Moderna stock rises as it works on a hantavirus vaccine after a cruise outbreak, but the disease is rare and vaccines will take years.
Moderna Beats Q1 2026 Revenue Estimates as International Sales Surge, Stock Jumps
Moderna beat Q1 revenue on strong overseas COVID vaccine sales, revenue $389M, smaller US demand, reported a per-share loss.
Moderna Pays Up to $2.25 Billion to End COVID Vaccine Patent War
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.
FDA Reverses Decision: Agrees to Review Moderna's New mRNA Flu Vaccine
The FDA has flipped its stance and will now review Moderna's mRNA-1010 flu vaccine for adults 50+, after an initial rejection caused controversy. Decision sets August 5, 2026, target date.